Fineline Cube

Follow:
14422 Articles
Eli Lilly Announces $6.5 B Houston Facility to Boost Synthetic‑Medicine API Production
Company

Eli Lilly Announces $6.5 B Houston Facility to Boost Synthetic‑Medicine API Production

Sino Biopharmaceutical Reports First‑Patient Enrollment for LM‑2417 Phase I Trial
CompanyDrug

Sino Biopharmaceutical Reports First‑Patient Enrollment for LM‑2417 Phase I Trial

MSD Teams with Variational AI in $349 Million Generative‑AI Drug Discovery Deal
CompanyDeals

MSD Teams with Variational AI in $349 Million Generative‑AI Drug Discovery Deal

ProBio and Immunofoco Forge Global CGT Manufacturing Alliance
CompanyDeals

ProBio and Immunofoco Forge Global CGT Manufacturing Alliance

Stealth BioTherapeutics Receives FDA Accelerated Approval for Forzinity in Barth Syndrome
CompanyDrug

Stealth BioTherapeutics Receives FDA Accelerated Approval for Forzinity in Barth Syndrome

China Drug Procurement: Centralized Rules Shape 11th Round Of VBP
Policy / Regulatory

China Drug Procurement: Centralized Rules Shape 11th Round Of VBP

Genrix Bio Secures Exclusive Deal for Vecantoxatug and Silevimig with CMS
CompanyDeals

Genrix Bio Secures Exclusive Deal for Vecantoxatug and Silevimig with CMS

Roche’s SC Lunsumio Gains CHMP Recommendation for Relapsed Follicular Lymphoma
CompanyDrug

Roche’s SC Lunsumio Gains CHMP Recommendation for Relapsed Follicular Lymphoma

Roche’s giredestrant Yields Positive PFS Results in evERA Phase III Study
CompanyDrug

Roche’s giredestrant Yields Positive PFS Results in evERA Phase III Study

Shanghai Sanyou Medical’s Agloe Robot Enters Chinese NMPA Special Review for Innovative Spine Devices
Medical Device

Shanghai Sanyou Medical’s Agloe Robot Enters Chinese NMPA Special Review for Innovative Spine Devices

Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR
CompanyDrug

Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR

Pfizer to Acquire Metsera for $4.9 B, Expanding Its Obesity & Cardiometabolic Pipeline
CompanyDeals

Pfizer to Acquire Metsera for $4.9 B, Expanding Its Obesity & Cardiometabolic Pipeline